Retlirafusp alfa Injection

DRUG4 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Peking University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, The First Affiliated Hospital of Zhengzhou University

Conditions

CRC (Colorectal Cancer)GEJ AdenocarcinomaGastric Adenocarcinoma and Gastroesophageal Junction AdenocarcinomaPancreatic Cancer

Phase 2

Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM

RecruitingNCT07728019

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCRC (Colorectal Cancer)

Start: 2026-07-30End: 2031-12-31Target: 60Updated: 2026-09-22

Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer

Not yet recruitingNCT07814859

The First Affiliated Hospital of Zhengzhou UniversityPancreatic Cancer

Start: 2026-08-31End: 2029-08-31Target: 88Updated: 2026-09-11

Phase 3

Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases

Not yet recruitingNCT07677293

Peking UniversityGastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

Start: 2026-06-26End: 2028-12-31Target: 332Updated: 2026-06-30

Unknown Phase

Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and Efficacy

Not yet recruitingNCT07493382

Tianjin Medical University Cancer Institute and HospitalGEJ Adenocarcinoma

Start: 2026-04-01End: 2029-04-01Target: 30Updated: 2026-03-25